Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Senzime AB ( (SE:SEZI) ).
Senzime AB has launched EMGINE, a next-generation software suite for its TetraGraph® platform, aimed at advancing neuromuscular monitoring. This new technology, which will be showcased at the ANESTHESIOLOGY 2025 conference, is built on extensive real-world data and offers enhanced patient safety and compliance with international guidelines. The EMGINE software, featuring advanced algorithms and noise-reduction technology, is expected to strengthen Senzime’s position in the medical device industry by providing hospitals with state-of-the-art monitoring capabilities.
The most recent analyst rating on (SE:SEZI) stock is a Hold with a SEK6.00 price target. To see the full list of analyst forecasts on Senzime AB stock, see the SE:SEZI Stock Forecast page.
More about Senzime AB
Senzime is a leading medical device company established in 1999, specializing in precision-based monitoring systems that enhance perioperative patient safety. Its flagship product, the TetraGraph® system, is widely used in operating rooms globally to monitor neuromuscular transmission during surgery, ensuring accurate dosing of paralytic drugs. Headquartered in Uppsala, Sweden, Senzime is publicly traded on the Nasdaq Stockholm Main Market and the US OTCQX Market.
Average Trading Volume: 580,957
Technical Sentiment Signal: Sell
Current Market Cap: SEK935.4M
See more data about SEZI stock on TipRanks’ Stock Analysis page.